Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Dermatologic 1

Conditions

Melanoma 8Neoplasms 2Carcinoma, Non-Small-Cell Lung 2Carcinoma, Basal Cell 2Urologic Neoplasms 1Urogenital Neoplasms 1Urogenital Diseases 1Urinary Bladder Neoplasms 1Urinary Bladder Diseases 1Squamous Cell Carcinoma of Head and Neck 1Neoplasms by Site 1Nasopharyngeal Carcinoma 1Muscle Invasive Bladder Urothelial Carcinoma 1Melanoma, Cutaneous Malignant 1Male Urogenital Diseases 1Locally Advanced Melanoma 1Female Urogenital Diseases and Pregnancy Complications 1Female Urogenital Diseases 1Colorectal Neoplasms 1Colonic Neoplasms 1Carcinoma, Transitional Cell 1Carcinoma, Renal Cell 1Carcinoma, Merkel Cell 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 9Nivolumab 5aldesleukin 2Specimen Handling 2Magnetic Resonance Spectroscopy 2Ipilimumab 2Interleukin-2 2Cyclophosphamide 2Biopsy 2sargramostim 1relatlimab 1regorafenib 1prednylidene 1lutetium Lu 177 dotatate 1fludarabine phosphate 1fludarabine 1deltacortene 1avelumab 1aflibercept 1X-Rays 1Sirolimus 1Sentinel Lymph Node Biopsy 1Radiotherapy 1Prednisone 1Predictive Learning Models 1Paclitaxel 1Opdualag 1NEO212 1Lidocaine, Prilocaine Drug Combination 1Laparoscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Recruiting × Carcinoma, Merkel Cell × relatlimab × Clear all
NCT06151236 2026-02-17

Neoadjuvant Nivolumab and Relatlimab in Merkel Cell Carcinoma

Melanoma Institute Australia

Phase 2 Recruiting
20 enrolled
Dermatologic

Carcinoma, Merkel Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡